Delivery Order SPE2DB22D1200-SPE2DB25FN4EX
- Not listed
- The Defense Logistics Agency awarded a $17,094.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 29, 2025, with completion expected by September 2, 2025. This firm fixed price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions including...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) with a ceiling value of $68,694.01 on August 11, 2025, with final completion by August 12, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open bidding. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on August 18, 2025, with an ultimate completion date of August 19, 2025. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The contract utilizes firm fixed pricing with no set-aside designation, indicating open competition. AmerisourceBergen...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $59,336.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL). The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $42,441.91. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $6,447.84 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitive, firm fixed-price delivery order is scheduled for completion by August 4, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN4EXDelivery Order
The Defense Logistics Agency awarded a $14,249.13 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen units on September 4, 2025, with an ultimate completion date of September 5, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions including atopic dermatitis, asthma, and chronic rhinosinusitis. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. This prime contract vehicle serves as a comprehensive pharmaceutical support platform enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates extensive experience fulfilling DLA medical procurement requirements across multiple therapeutic domains, supporting military healthcare systems, the Defense Health Agency, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 9/4/25 |